Berenberg Bank Reiterates “Hold” Rating for Smith & Nephew (SN)

Berenberg Bank restated their hold rating on shares of Smith & Nephew (LON:SN) in a research report released on Monday morning. Berenberg Bank currently has a GBX 1,370 ($18.58) target price on the stock.

A number of other research firms have also commented on SN. JPMorgan Chase restated an overweight rating on shares of Smith & Nephew in a research note on Wednesday, April 25th. Credit Suisse Group reaffirmed a neutral rating and issued a GBX 1,290 ($17.50) target price on shares of Smith & Nephew in a report on Tuesday, April 24th. Jefferies Group reaffirmed a buy rating on shares of Smith & Nephew in a report on Thursday, April 12th. Deutsche Bank reaffirmed a hold rating and issued a GBX 1,309.50 ($17.76) target price (down previously from GBX 1,315 ($17.84)) on shares of Smith & Nephew in a report on Tuesday, April 17th. Finally, HSBC raised Smith & Nephew to a buy rating and raised their target price for the company from GBX 1,320 ($17.91) to GBX 1,530 ($20.75) in a report on Monday, March 26th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of GBX 1,387.68 ($18.82).

Smith & Nephew stock opened at GBX 1,319 ($17.89) on Monday. Smith & Nephew has a one year low of GBX 1,173 ($15.91) and a one year high of GBX 1,442 ($19.56).

In other news, insider Graham Baker acquired 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were bought at an average price of GBX 1,283 ($17.40) per share, with a total value of £12,830 ($17,403.69). Also, insider Olivier Bohuon sold 8,171 shares of the firm’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of GBX 1,301 ($17.65), for a total value of £106,304.71 ($144,200.64).

About Smith & Nephew

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.

Leave a Reply